Lite Strategy, Inc. (LITS)
| Market Cap | $24.12M-58.0% |
| Revenue (ttm) | n/a |
| Net Income | -$51.49M |
| EPS | -$1.41 |
| Shares Out | 29.88M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Nov 16, 2023 |
| Volume | 148,448 |
| Open | $0.80 |
| Previous Close | $0.79 |
| Day's Range | $0.77 - $0.82 |
| 52-Week Range | $0.69 - $1.99 |
| Beta | 0.04 |
| Analysts | none |
| Price Target | n/a |
| Earnings Date | Nov 13, 2026 |
About LITS
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. It is also involved in holding Litecoin tokens as a primary reserve asset. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
Lite Strategy, Inc. Stock Analysis — InsiderScore
Lite Strategy, Inc. scored higher than 62% of companies evaluated by InsiderBuying, and ranked 76th out of 239 stocks in the financials sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Lite Strategy, Inc. bought $21.5K of stock across 1 purchase in the last 90 days, the largest of them $21.5K.
The average purchase added about 22% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$LITS stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in LITS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by LITS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
LITS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
LITS Revenue by Segment
| Cash and cash equivalents | $4.28M | 53.78% |
| Loss on derivative liabilities, net | $1.17M | 14.72% |
| Investments in SAFE and Token Warrants, at fair value | $1.04M | 13.12% |
| Professional fees | $651.00K | 8.18% |
| Asset management fee and advisory fees | $516.00K | 6.48% |
| Legal fees | $296.00K | 3.72% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New LITS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to LITS from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from LITS’s recent data — informational, not investment advice
